Evidence map›Paper›PMID 42547659›Full record

ArticleJournal of neuro-oncology2026

Multi-molecular saturation-transfer MR fingerprinting for differentiating tumor progression from treatment-related change in post-treatment IDH-wildtype glioblastoma: a feasibility study.

Kevin Ju, Ji Eun Park, Sultan Z Mahmud, Lindsay Blair, Doris D M Lin, Peter C M van Zijl, David O Kamson, Hye-Young Heo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kevin Ju *Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ji Eun Park *Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sultan Z MahmudDepartment of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Lindsay BlairDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.
Doris D M LinDepartment of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Peter C M van ZijlDepartment of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
David O KamsonDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.
Hye-Young HeoDepartment of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA. hheo1@jhmi.edu.ORCID http://orcid.org/0000-0002-7297-2015

Funding

TRD 4: Platforms for multi-modal and multi-scale imaging dataP41EB031771 · NIBIB · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI Hanzhang Lu, Peter CM Van Zijl · 2021 to 2026
$9.9M
Chemical Exchange Saturation Transfer MR FingerprintingR01EB029974 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI HEO, HYE YOUNG · 2021 to 2024
$1.4M
NIBIB NIH HHS P41 EB031771NIBIB NIH HHS R01 EB029974NIH HHS NIH R01EB029974NIH HHS P41EB031771
6 · The paper itself

Abstract

purposeTo determine whether quantitative molecular parameters derived from saturation transfer MR fingerprinting (ST-MRF) can differentiate tumor progression from treatment-related change and provide prognostic information in IDH-wildtype glioblastoma. MATERIALS AND

methodsIn this retrospective single-center study, 24 patients (median age, 59.5 years; interquartile range, 47-68.5 years) with histologically confirmed glioblastoma underwent ST-MRF on a 3-T clinical MRI system for suspected progression after concurrent chemoradiation therapy. ST-MRF parameters included amide proton transfer (APT), Amine-CEST, relayed nuclear Overhauser enhancement (rNOE), and magnetization transfer contrast (MTC) components. Tumor progression versus treatment-related change was determined by pathology or clinico-radiologic consensus using RANO 2.0 criteria. Diagnostic performance was assessed with logistic regression and receiver operating characteristic analysis. Overall survival (OS) was evaluated with Cox proportional hazards models and Harrell's concordance index (C-index).

resultsTumor progression demonstrated significantly higher APT1µT (11.2 ± 0.8% vs. 10.0 ± 0.7%, P < .001) and APT2µT (12.0 ± 1.6% vs. 10.3 ± 1.3%, P = .004), while lower MTCs (all APT-, Amine-, and rNOE-MTC, largest P = .016) compared with treatment-related change. APT1µT showed the highest diagnostic performance (AUC, 0.88; 95% CI: 0.70-0.97), followed by APT2µT (AUC, 0.80; 95% CI: 0.61-0.93). Higher APT1µT (hazard ratio [HR], 1.95; P = .029) and APT2µT (HR, 1.53; P = .037) were significantly associated with shorter OS, with the highest prognostic performance for APT2µT (C-index, 0.70; 95% CI: 0.60-0.80).

conclusionIn this exploratory study, ST-MRF-derived molecular imaging parameters, particularly APT, showed feasibility for differentiating tumor progression from treatment-related change after treatment and potential for providing prognostic information.

Indexed as

Brain NeoplasmsGlioblastomaMagnetic Resonance ImagingAgedChemoradiotherapyDisease ProgressionFeasibility StudiesFemaleFollow-Up StudiesHumansIsocitrate DehydrogenaseMaleMiddle AgedPrognosisRetrospective StudiesIsocitrate DehydrogenaseGlioblastomaMR fingerprintingSaturation transferTreatment related changeTumor progression

Identifiers

PMID42547659
PMCPMC13505793

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.